: FDA advisers vote in favor of Biogen and Eisai’s collaborative Alzheimer’s treatment

If granted full FDA approval, which could come in early July, treatment could boost annual Medicare spending by nearly $9 billion, analysis shows.

Previous post Personal Finance Daily: Want to fight your office’s return-to-work mandate? The law isn’t on your side and why wildfire smoke is so dangerous for the lungs
Next post Economic Report: Banks increase lending for third straight week